5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Glioblastoma Multiforme (GBM) · Glioblastoma Multiform (Grade IV Astrocytoma) · Diffuse Hemispheric Glioma, H3 G34-Mutant · Malignant Primary Gliomas

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cambridge University Hospitals, Cambridge, United Kingdom
Contact: Study coordinator (Mareike Thompson, MD) · mareike.thompson3@nhs.net · +44 (0)12 2358 6705
The Royal Marsden Hospital - Drug Development Unit, Sutton, United Kingdom
Contact: Study coordinator (Juanita Lopez, MD, PhD) · juanita.lopez@icr.ac.uk · +44 (0)20 86613539
The Royal Marsden Hospital - Neuro-Oncology Unit, Sutton, United Kingdom
Contact: Study coordinator (Liam Welsh, MD) · Liam.Welsh@rmh.nhs.uk · +44 (0)20 8661 3826

Study leads

Juanita Lopez, MD, PhD
Study Director
National Health Service, UK

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

Brain Tumor · Brain Metastases · Brain Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

Malignant Glioma of Brain · Astrocytoma · Malignant Astrocytoma

Abroad (travel likely)RecruitingPHASE1

Detroit, United States

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Glioblastoma (GBM) · Newly Diagnosed Glioblastoma · GBM

Abroad (travel likely)RecruitingPHASE2

Springdale, United States · Los Angeles, United States

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

Glioblastoma Multiforme (GBM) · Glioblastoma · Glioma of Brain

Abroad (travel likely)RecruitingPHASE1, PHASE2

New York, United States